天宸股份(600620.SH):天宸健康公司全體股東同意按股權比例向其提供借款額度9000萬元
格隆匯 11 月 20日丨天宸股份(600620.SH)公佈,鑑於公司控股子公司上海天宸健康管理有限公司(“天宸健康公司”)的“天宸健康城”項目開發在即,為保證項目建設工作正常推進,天宸健康公司全體股東同意按股權比例向其提供借款額度總計9000萬元,借款期限為一年,期限自2020年11月21日起至2021年11月20日止。借款期間按本協議生效之日全國銀行間同業拆借中心公佈的一年期貸款市場報價利率(LPR)支付借款利息,按股東借款實際資金使用天數計息,相應利息應在借款歸還時同時支付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.